IP Library Assignment 070531/0487
Patent Assignment
Reel/Frame 070531/0487

Confirmatory Grant of Security Interest in United States Patents

Recorded: 2025-03-17 Pages: 32
Assignors
ARBOR PHARMACEUTICALS, LLC
Executed: 2025-03-14
AZURITY PHARMACEUTICALS, INC.
Executed: 2025-03-14
SILVERGATE PHARMACEUTICALS, INC.
Executed: 2025-03-14
Assignee
HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
40 WEST 57TH STREET, 33RD FLOOR, NEW YORK, NEW YORK, 10019
Covered Properties (189)
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Patent: 6,818,787 →
Application: 10/171,485 →
Publication: US 2003/0176398
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Patent: 7,109,239 →
Application: 10/932,374 →
Publication: US 2005/0107334
Crystalline Form of Y-Aminobutyric Acid Analog
Patent: 8,026,279 →
Application: 10/966,507 →
Publication: US 2005/0154057
Treating or Preventing Restless Legs Syndrome Using Prodrugs of Gaba Analogs
Patent: 8,114,909 →
Application: 10/969,196 →
Publication: US 2005/0192353
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Patent: 7,227,028 →
Application: 11/026,491 →
Publication: US 2005/0222431
Container and Method for the Preparation, Storage and Dispensing of Compounded Suppositories
Patent: 7,434,690 →
Application: 11/093,178 →
Publication: US 2005/0241982
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Patent: 8,048,917 →
Application: 11/110,909 →
Publication: US 2006/0229361
Gaba Analog Prodrug Sustained Release Oral Dosage Forms
Patent: 8,795,725 →
Application: 11/269,045 →
Publication: US 2006/0141034
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Patent: 7,300,956 →
Application: 11/508,131 →
Publication: US 2007/0054945
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Patent: 7,511,158 →
Application: 11/754,232 →
Publication: US 2007/0244331
Topical Avermectin Formulations and Methods for Elimination and Prophylaxis of Susceptible and Treatment-Resistant Strains of Head Lice
Patent: 8,791,153 →
Application: 11/871,660 →
Publication: US 2008/0214657
Container and Kit for the Preparation, Storage and Dispensing of Compounded Suppositories
Patent: 7,815,929 →
Application: 12/207,957 →
Publication: US 2009/0028964
Crystalline Form of a (3S)-Aminomethyl-5-Methyl-Hexanoic Acid Prodrug and Methods of Use
Patent: 7,872,046 →
Application: 12/358,454 →
Publication: US 2009/0215809
Enantiomerically Resolving Acyloxyalkyl Thiocarbonates Used in Synthesizing Acyloxyalkyl Carbamate Prodrugs
Patent: 8,062,870 →
Application: 12/358,532 →
Publication: US 2009/0192325
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Patent: 8,003,809 →
Application: 12/390,000 →
Publication: US 2009/0216037
Methods of Synthesizing N-Hydroxysuccinimidyl Carbonates
Patent: 7,989,641 →
Application: 12/537,764 →
Publication: US 2010/0081830
Prodrugs of Methyl Hydrogen Fumarate, Pharmaceutical Compositions Thereof, and Methods of Use
Patent: 8,148,414 →
Application: 12/544,133 →
Publication: US 2010/0048651
Sustained Release Oral Dosage Forms of an R-Baclofen Prodrug
Application: 12/717,098 →
Publication: US 2010/0255093
Container and Kit for the Preparation, Storage and Dispensing of Compounded Suppositories
Patent: 8,276,757 →
Application: 12/902,260 →
Publication: US 2011/0024322
Topical Avermectin Formulations and Methods for Elimination and Prophylaxis of Susceptible and Treatment Resistant Strains of Head Lice
Patent: 8,927,595 →
Application: 13/116,547 →
Publication: US 2011/0275582
CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG
Patent: 8,686,034 →
Application: 13/164,620 →
Publication: US 2011/0313036
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Patent: 8,378,137 →
Application: 13/208,176 →
Publication: US 2012/0010425
Prodrugs of Methyl Hydrogen Fumarate, Pharmaceutical Compositions Thereof, and Methods of Use
Patent: 8,778,991 →
Application: 13/274,282 →
Publication: US 2012/0157523
Methods of Using Prodrugs of Methyl Hydrogen Fumarate and Pharmaceutical Compositions Thereof
Patent: 8,785,443 →
Application: 13/274,284 →
Publication: US 2012/0095003
Enalapril Compositions
Patent: 8,568,747 →
Application: 13/670,355 →
Enalapril Compositions
Patent: 8,778,366 →
Application: 13/914,452 →
Publication: US 2014/0100260
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Patent: 9,597,292 →
Application: 13/973,456 →
Publication: US 2014/0065211
Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
Application: 13/973,700 →
Publication: US 2014/0057917
Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use
Patent: 9,139,517 →
Application: 14/076,406 →
Publication: US 2014/0066501
CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG
Patent: 9,150,503 →
Application: 14/206,893 →
Publication: US 2014/0235710
Pharmaceutical Compositions of Dimethyl Fumarate
Application: 14/223,026 →
Publication: US 2014/0284245
Sotalol Compositions and Uses of the Same
Patent: 9,724,297 →
Application: 14/242,624 →
Publication: US 2015/0272882
Methods of Using Prodrugs of Methyl Hydrogen Fumarate and Pharmaceutical Compositions Thereof
Patent: 9,452,972 →
Application: 14/298,668 →
Publication: US 2014/0329818
Method of Making Monomethyl Fumarate
Patent: 9,302,977 →
Application: 14/298,713 →
Publication: US 2014/0364604
Gaba Analog Prodrug Sustained Release Oral Dosage Forms
Patent: 8,906,412 →
Application: 14/309,662 →
Publication: US 2014/0302140
Crystalline Forms of (N,N-Diethylcarbamoyl)Methyl Methyl (2E)but-2-Ene-1,4-Dioate, Methods of Synthesis and Use
Patent: 9,416,096 →
Application: 14/478,627 →
Publication: US 2015/0073049
Pharmaceutical Compositions of Fumaric Acid Esters
Patent: 9,999,672 →
Application: 14/663,649 →
Publication: US 2015/0265707
Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use
Patent: 9,265,748 →
Application: 14/799,012 →
Publication: US 2015/0313865
Lisinopril Formulations
Patent: 9,463,183 →
Application: 14/934,752 →
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Application: 14/990,582 →
Publication: US 2016/0113879
Container and Method for the Preparation, Storage and Dispensing of Compounded Suppositories
Patent: 9,918,903 →
Application: 15/006,745 →
Publication: US 2016/0213567
Enalapril Formulations
Patent: 9,669,008 →
Application: 15/081,603 →
Composition and Method for Vancomycin Oral Liquid
Application: 15/126,059 →
Publication: US 2017/0079910
Crystalline Forms of (N,N-Diethylcarbamoyl)Methyl Methyl (2E)but-2-Ene-1,4-Dioate, Methods of Synthesis and Use
Patent: 9,682,057 →
Application: 15/214,563 →
Publication: US 2017/0042853
Lisinopril Formulations
Patent: 9,616,096 →
Application: 15/268,095 →
Publication: US 2017/0119840
Gaba Analog Prodrug Sustained Release Oral Dosage Forms
Patent: 9,949,941 →
Application: 15/359,321 →
Publication: US 2017/0071888
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Patent: 9,944,592 →
Application: 15/388,870 →
Publication: US 2017/0190657
Enalapril Compositions
Patent: 9,855,214 →
Application: 15/433,743 →
Publication: US 2017/0181968
Lisinopril Formulations
Patent: 9,814,751 →
Application: 15/483,691 →
Publication: US 2017/0209523
Crystalline Forms of (N, N-Diethylcarbamoyl)Methyl Methyl (2E)but-2-Ene-1,4-Dioate, Methods of Synthesis and Use
Patent: 9,795,581 →
Application: 15/589,087 →
Publication: US 2017/0239206
Enalapril Formulations
Patent: 9,808,442 →
Application: 15/613,622 →
Publication: US 2017/0266159
Sotalol Compositions and Uses of the Same
Application: 15/635,499 →
Publication: US 2017/0296493
Crystalline Forms of (N, N-Diethylcarbamoyl)Methyl Methyl (2E)but-2-Ene-1,4-Dioate, Methods of Synthesis and Use
Patent: 9,895,336 →
Application: 15/696,616 →
Publication: US 2017/0368014
Amlodipine Formulations
Application: 15/726,901 →
Publication: US 2018/0098978
Composition and Method for Vancomycin Oral Liquid
Application: 15/791,717 →
Publication: US 2018/0116955
Enalapril Formulations
Application: 15/802,341 →
Publication: US 2018/0055821
Lisinopril Formulations
Application: 15/805,934 →
Publication: US 2018/0078604
Enalapril Compositions
Patent: 9,968,553 →
Application: 15/850,732 →
Publication: US 2018/0116954
Non-Aqueous Liquid Nimodipine Compositions
Application: 15/954,357 →
Publication: US 2019/0224180
Pharmaceutical Compositions of Fumaric Acid Esters
Application: 15/980,279 →
Publication: US 2019/0117776
Enalapril Formulations
Application: 16/003,994 →
Publication: US 2018/0289669
Lisinopril Formulations
Application: 16/053,164 →
Publication: US 2018/0339011
Ready-To-Use Injectable Pharmaceutical Compositions Comprising Neostigmine and Glycopyrrolate
Application: 16/170,948 →
Publication: US 2019/0374462
Powder for Oral Suspension Containing Lamotrigine
Application: 16/171,914 →
Publication: US 2019/0060237
Ready-To-Use Injectable Pharmaceutical Compositions Comprising Neostigmine and Glycopyrrolate
Application: 16/176,866 →
Enalapril Formulations
Application: 16/177,159 →
Publication: US 2019/0070147
Pharmaceutical Compositions of Dimethyl Fumarate
Application: 16/206,521 →
Publication: US 2019/0091196
Enalapril Formulations
Application: 16/242,898 →
Publication: US 2019/0142797
Sotalol Compositions and Uses of the Same
Application: 16/243,440 →
Publication: US 2019/0142772
Lisinopril Formulations
Application: 16/295,482 →
Publication: US 2019/0201475
Composition and Method for Proton Pump Inhibitor Suspension
Application: 16/310,675 →
Publication: US 2019/0321348
Apparatus and Method for Filling Bulk Materials into a Container
Application: 16/318,819 →
Publication: US 2019/0185187
Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof
Application: 16/354,764 →
Publication: US 2019/0209529
Pharmaceutical Compositions of Testosterone
Application: 16/363,376 →
Publication: US 2019/0307772
Pharmaceutical Compositions of Meloxicam
Application: 16/371,293 →
Publication: US 2019/0307681
Amlodipine Formulations
Application: 16/381,575 →
Publication: US 2019/0314279
Non-Aqueous Liquid Nimodipine Compositions
Application: 16/407,980 →
Publication: US 2019/0262326
Pharmaceutical Compositions of Posaconazole
Application: 16/410,149 →
Publication: US 2020/0237753
Midodrine Hydrochloride Oral Solution and Uses Thereof
Application: 16/469,101 →
Publication: US 2020/0113851
Compositions and Kits for Omeprazole Suspension
Application: 16/513,604 →
Composition and Method for Vancomycin Oral Liquid
Application: 16/676,325 →
Publication: US 2020/0069584
Pharmaceutical Compositions of Lurasidone
Application: 16/697,415 →
Publication: US 2020/0222394
Non-Aqueous Liquid Nimodipine Compositions
Application: 16/722,513 →
Publication: US 2020/0121662
Pharmaceutical Compositions of Dimethyl Fumarate
Application: 16/749,427 →
Publication: US 2020/0155496
Pharmaceutical Compositions of Lurasidone
Application: 16/774,457 →
Publication: US 2020/0222395
Pharmaceutical Compositions of Nilotinib
Application: 16/793,833 →
Publication: US 2020/0261449
Lisinopril Formulations
Application: 16/822,412 →
Publication: US 2020/0237851
Topical Avermectin Formulations and Methods for Elimination and Prophylaxis of Susceptible and Treatment Resistant Strains of Head Lice
Application: 16/825,476 →
Publication: US 2020/0221700
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Application: 16/853,168 →
Publication: US 2020/0246271
Amlodipine Formulations
Application: 16/853,380 →
Publication: US 2020/0246320
Enalapril Formulations
Application: 16/883,553 →
Publication: US 2020/0281893
Composition and Method for Vancomycin Oral Liquid
Application: 16/892,421 →
Publication: US 2020/0306186
Amlodipine Formulations
Application: 16/927,664 →
Publication: US 2020/0338054
Amlodipine Formulations
Application: 16/927,678 →
Publication: US 2020/0338055
Composition and Method for Vancomycin Oral Liquid
Application: 16/941,400 →
Publication: US 2020/0360283
Composition and Method for Vancomycin Oral Liquid
Application: 16/941,414 →
Publication: US 2020/0352858
Pharmaceutical Compositions of Nilotinib
Application: 16/953,728 →
Publication: US 2021/0077485
Enalapril Formulations
Application: 16/991,575 →
Publication: US 2020/0368200
Compositions and Kits for Omeprazole Suspension
Application: 16/998,731 →
Publication: US 2021/0346363
Compositions and Kits for Omeprazole Suspension
Application: 17/017,295 →
Publication: US 2021/0069167
Stable Pharmaceutical Compositions of Dihydroergotamine Mesylate
Application: 17/028,863 →
Publication: US 2021/0085657
Sotalol Compositions and Uses of the Same
Application: 17/036,790 →
Publication: US 2021/0077435
Amlodipine Formulations
Application: 17/067,396 →
Publication: US 2021/0023003
Suspensions and Diluents for Metronidazole and Baclofen
Application: 17/133,415 →
Publication: US 2021/0220267
Enalapril Formulations
Application: 17/150,587 →
Publication: US 2021/0137882
Amlodipine Formulations
Application: 17/194,016 →
Publication: US 2021/0186942
Lisinopril Formulations
Application: 17/194,021 →
Publication: US 2021/0187055
Enalapril Formulations
Application: 17/228,024 →
Publication: US 2021/0251956
Enalapril Formulations
Application: 17/338,436 →
Publication: US 2021/0299092
Amlodipine Formulations
Application: 17/345,943 →
Publication: US 2021/0308049
Ready-To-Use Injectable Pharmaceutical Compositions Comprising Neostigmine and Glycopyrrolate
Application: 17/386,139 →
Publication: US 2021/0369604
Compositions and Kits for Omeprazole Suspension
Application: 17/463,258 →
Publication: US 2022/0031683
Lisinopril Formulations
Application: 17/507,144 →
Publication: US 2022/0111000
Non-Aqueous Liquid Nimodipine Compositions
Application: 17/530,728 →
Publication: US 2022/0071974
Pharmaceutical Compositions of Dimethyl Fumarate
Application: 17/551,550 →
Publication: US 2022/0105067
Composition and Method for Proton Pump Inhibitor Suspension
Application: 17/554,737 →
Publication: US 2022/0152007
Non-Aqueous Liquid Nimodipine Compositions
Application: 17/558,924 →
Publication: US 2022/0110926
Compositions and Kits for Omeprazole Suspension
Application: 17/576,496 →
Publication: US 2022/0211852
Pharmaceutical Compositions of Cabozantinib
Application: 17/673,583 →
Publication: US 2022/0265633
Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof
Application: 17/695,410 →
Publication: US 2022/0202782
Pharmaceutical Compositions of Testosterone
Application: 17/696,319 →
Publication: US 2022/0202830
Liquid Nimodipine Compositions
Application: 17/708,669 →
Publication: US 2022/0218684
Amlodipine Formulations
Application: 17/716,505 →
Publication: US 2022/0296578
Suspensions and Diluents for Metronidazole and Baclofen
Application: 17/725,923 →
Publication: US 2022/0241197
Stable Pharmaceutical Compositions of Succinylcholine Chloride
Application: 17/822,399 →
Publication: US 2023/0086729
Stable Pharmaceutical Compositions of Succinylcholine Chloride
Application: 17/822,756 →
Publication: US 2023/0091021
Pharmaceutical Compositions of Mifepristone
Application: 17/843,669 →
Publication: US 2023/0085008
Stable Pharmaceutical Compositions of Clonidine
Application: 17/866,115 →
Publication: US 2023/0149359
Stable Pharmaceutical Compositions of Bendamustine
Application: 17/877,476 →
Amlodipine Formulations
Application: 17/892,738 →
Publication: US 2022/0401363
Stable Pharmaceutical Compositions of Cyclophosphamide
Application: 17/961,943 →
Publication: US 2023/0119069
Composition and Method for Vancomycin Oral Liquid
Application: 17/965,253 →
Publication: US 2023/0102830
Liquid Nimodipine Compositions
Application: 17/974,027 →
Publication: US 2023/0068944
Liquid Nimodipine Compositions
Application: 17/974,032 →
Publication: US 2023/0053961
Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof
Application: 17/975,789 →
Publication: US 2023/0046943
Stable Liquid Compositions of Netupitant and Palonosetron
Application: 18/069,204 →
Publication: US 2023/0190737
Ready-To-Use Injectable Pharmaceutical Compositions Comprising Neostigmine and Glycopyrrolate
Application: 18/098,505 →
Publication: US 2023/0149294
Pharmaceutical Compositions of Cabozantinib
Application: 18/108,423 →
Publication: US 2023/0181561
Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof
Application: 18/114,410 →
Publication: US 2023/0241036
Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof
Application: 18/114,469 →
Publication: US 2023/0218586
Stable Pharmaceutical Compositions of Apixaban
Application: 18/117,808 →
Publication: US 2023/0285368
Compositions and Kits for Omeprazole Suspension
Application: 18/128,344 →
Publication: US 2023/0233682
Compositions and Kits for Omeprazole Suspension
Application: 18/128,451 →
Publication: US 2023/0248830
Compositions and Kits for Omeprazole Suspension
Application: 18/128,550 →
Publication: US 2023/0270862
Stable Pharmaceutical Compositions of Hydroxyurea
Application: 18/163,811 →
Publication: US 2023/0301945
Stable Liquid Compositions of Glucagon
Application: 18/202,103 →
Publication: US 2023/0381282
Amlodipine Formulations
Application: 18/203,266 →
Publication: US 2023/0338287
Non-Aqueous Liquid Nimodipine Compositions
Application: 18/244,168 →
Publication: US 2023/0414592
Pharmaceutical Compositions of Testosterone
Application: 18/299,493 →
Publication: US 2023/0248742
Pharmaceutical Compositions of Cabozantinib
Application: 18/312,857 →
Publication: US 2023/0270736
Stable Pharmaceutical Compositions of Bendamustine
Application: 18/328,392 →
Publication: US 2023/0310384
Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
Application: 18/333,804 →
Publication: US 2024/0024249
Stable Pharmaceutical Compositions of Edaravone
Application: 18/340,067 →
Publication: US 2024/0285582
Suspensions and Diluents for Metronidazole and Baclofen
Application: 18/402,960 →
Publication: US 2024/0285527
Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
Application: 18/419,926 →
Publication: US 2024/0240229
Stable Pharmaceutical Compositions of Apixaban
Application: 18/420,099 →
Publication: US 2024/0197705
Amlodipine Formulations
Application: 18/420,901 →
Publication: US 2024/0252433
Ready-To-Use Injectable Pharmaceutical Compositions Comprising Neostigmine and Glycopyrrolate
Application: 18/444,310 →
Publication: US 2024/0189222
Lisinopril Formulations
Application: 18/450,553 →
Publication: US 2023/0405079
Pharmaceutical Compositions of Nilotinib
Application: 18/468,266 →
Publication: US 2024/0009188
Liquid Nimodipine Compositions
Application: 18/484,564 →
Publication: US 2024/0082230
Stable Antiemetic Emulsions for Parenteral Administration
Application: 18/487,330 →
Publication: US 2024/0156829
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Application: 18/492,882 →
Publication: US 2024/0197661
Sotalol Compositions and Uses of the Same
Application: 18/502,197 →
Publication: US 2024/0139131
Stable Pharmaceutical Compositions of Bendamustine
Application: 18/502,396 →
Publication: US 2024/0075014
Pharmaceutical Compositions of Cabozantinib
Application: 18/523,274 →
Publication: US 2024/0131018
Stable Pharmaceutical Compositions of Succinylcholine Chloride
Application: 18/528,684 →
Publication: US 2024/0108571
Pharmaceutical Compositions of Mifepristone
Application: 18/530,815 →
Publication: US 2024/0122944
Pharmaceutical Liquid Compositions of Meloxicam
Application: 18/542,163 →
Publication: US 2024/0139204
Pharmaceutical Compositions of Dimethyl Fumarate
Application: 18/582,320 →
Publication: US 2024/0189271
Lisinopril Formulations
Application: 18/663,349 →
Publication: US 2024/0299485
Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof
Application: 18/665,824 →
Publication: US 2025/0352468
Stable Pharmaceutical Compositions of Bendamustine
Application: 18/758,225 →
Publication: US 2024/0350459
Amlodipine Formulations
Application: 18/794,128 →
Publication: US 2024/0390347
Stable Liquid Compositions of Netupitant and Palonosetron
Application: 18/794,778 →
Publication: US 2024/0390365
Pharmaceutical Compositions of Fumaric Acid Esters
Application: 18/799,508 →
Publication: US 2025/0114457
Stable Liquid Compositions of Glucagon
Application: 18/896,310 →
Publication: US 2025/0032586
Pharmaceutical Compositions of Cabozantinib
Application: 18/901,359 →
Publication: US 2025/0025456
Pharmaceutical Compositions of Mifepristone
Application: 18/904,225 →
Publication: US 2025/0057855
Pharmaceutical Compositions of Testosterone
Application: 18/911,778 →
Publication: US 2025/0032508
Stable Pharmaceutical Compositions of Cyclophosphamide
Application: 18/925,887 →
Publication: US 2025/0049824
Stable Pharmaceutical Compositions of Apixaban
Application: 18/962,435 →
Publication: US 2025/0082617
Lisinopril Formulations
Application: 18/979,962 →
Publication: US 2025/0186533
Stable Pharmaceutical Compositions of Apixaban
Application: 18/985,229 →
Publication: US 2025/0221978
Non-Aqueous Liquid Nimodipine Compositions
Application: 19/009,120 →
Publication: US 2025/0221974
Stable Pharmaceutical Compositions of Clonidine
Application: 19/021,882 →
Publication: US 2025/0152558
Stable Pharmaceutical Compositions of Hydroxyurea
Application: 19/036,569 →
Publication: US 2025/0170078
Syringe
Patent: 836,772 →
Application: 29/657,824 →
Syringe
Patent: 851,757 →
Application: 29/668,705 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Merger Aug 16, 2013
From: TOPAZ PHARMACEUTICALS INC.
To: SANOFI - TOPAZ, INC.
Reel/Frame 031024/0502 →
Change of Name Aug 16, 2013
From: TOPAZ PHARMACEUTICALS LLC
To: TOPAZ PHARMACEUTICALS INC.
Reel/Frame 031031/0051 →
Corrective Assignment to Correct the Execution Date of Inventor Garry T. Gwozdz Previously Recorded on Reel 020836 Frame 0391. Assignor(S) Hereby Confirms the Execution Date of Inventor Garry T. Gwozdz Is 03/26/2008. Aug 23, 2013
From: GWOZDZ, GARRY T.; SPRING, NICHOLAS
To: TOPAZ PHARMACEUTICALS LLC
Reel/Frame 031076/0144 →
Security Agreement Dec 16, 2014
From: CUTISPHARMA, INC.; RXEDESIGNEDMEDS, LLC; RXM THERAPEUTICS, LLC
To: SILICON VALLEY BANK
Reel/Frame 034648/0882 →
Security Interest Nov 11, 2015
From: ARBOR PHARMACEUTICALS, LLC
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS AGENT
Reel/Frame 037013/0177 →
Assignment of Assignor's Interest Dec 2, 2015
From: SANOFI-TOPAZ INC.
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 037190/0575 →
Security Interest Jul 6, 2016
From: ARBOR PHARMACEUTICALS, LLC; XENOPORT, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 039266/0345 →
Assignment of Assignor's Interest Nov 10, 2017
From: MOSHER, GEROLD L.; MILES, DAVID W.
To: SILVERGATE PHARMACEUTICALS, INC.
Reel/Frame 044090/0243 →
Security Interest Mar 21, 2018
From: CUTISPHARMA, INC.
To: GOLDMAN SACHS SPECIALTY LENDING GROUP, L.P., AS COLLATERAL AGENT
Reel/Frame 045300/0385 →
Release of Security Interest Mar 22, 2018
From: SILICON VALLEY BANK
To: CUTISPHARMA, INC.
Reel/Frame 045311/0168 →
Assignment of Assignor's Interest Apr 20, 2018
From: ARBOR PHARMACEUTICALS, LLC
To: XENOPORT, INC.
Reel/Frame 046449/0306 →
Assignment of Assignor's Interest Jul 25, 2018
From: XENOPORT, INC.
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 046633/0753 →
Security Interest Dec 19, 2018
From: ARGENTUM HOLDINGS, LLC; SILVERGATE PHARMACEUTICALS, INC.
To: WHITE OAK HEALTHCARE FINANCE, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 047815/0615 →
Release of Security Interest May 17, 2019
From: GOLDMAN SACHS SPECIALTY LENDING GROUP, L.P., AS COLLATERAL AGENT
To: CUTISPHARMA, INC.
Reel/Frame 049212/0549 →
Release of Security Interest May 17, 2019
From: WHITE OAK HEALTHCARE FINANCE, LLC, AS AGENT
To: ARGENTUM HOLDINGS, LLC; SILVERGATE PHARMACEUTICALS, INC.
Reel/Frame 049211/0188 →
Security Interest May 17, 2019
From: CUTISPHARMA, INC.; SILVERGATE PHARMACEUTICALS, INC.
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 049209/0272 →
Security Interest Apr 16, 2021
From: SILVERGATE PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 055938/0895 →
Security Interest Apr 16, 2021
From: AZURITY PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 055938/0859 →
Assignment of Assignor's Interest Jun 3, 2021
From: SILVERGATE PHARMACEUTICALS, INC.
To: AZURITY PHARMACEUTICALS, INC.
Reel/Frame 056430/0743 →
Release of Security Interest Aug 23, 2021
From: GOLDMAN SACHS BANK USA
To: AZURITY PHARMACEUTICALS, INC.; SILVERGATE PHARMACEUTICALS, INC.
Reel/Frame 057253/0348 →
Release of Security Interest Aug 31, 2021
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 057346/0837 →
Security Interest Sep 20, 2021
From: AZURITY PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 057532/0424 →
Release of Security Interest Sep 20, 2021
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: SILVERGATE PHARMACEUTICALS, INC.
Reel/Frame 057531/0556 →
Security Interest Sep 20, 2021
From: ARBOR PHARMACEUTICALS, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 057544/0803 →
Release of Security Interest Sep 20, 2021
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AZURITY PHARMACEUTICALS, INC.
Reel/Frame 057531/0403 →